Merck Named One of America’s Most JUST Companies by JUST Capital and CNBC, Industry Leader in Pharmaceuticals and Biotech
10 Januar 2023 - 3:00PM
Business Wire
The JUST 100 is the only ranking that
recognizes companies doing right by all their stakeholders as
defined by the American public.
Merck (NYSE: MRK), known as MSD outside of the United States and
Canada, was named one of America’s Most JUST Companies, making this
the sixth consecutive year that Merck has been recognized for its
commitment to serving its workers, customers, communities, the
environment, and shareholders. Merck ranked No. 26 overall and
ranked No. 1 in the pharmaceuticals and biotech industry for the
third straight year, notably also ranking as the top company for
communities and customers in the industry.
“We are honored to be recognized as America’s Most JUST Company
in the pharmaceutical and biotech industry for the third year in a
row. This recognition demonstrates our company’s longstanding
commitment to operating responsibly on behalf of society,
shareholders and all our stakeholders to enable a safe, sustainable
and healthy future for patients and communities around the world,”
said Robert M. Davis, chairman and chief executive officer,
Merck.
For the annual Rankings, JUST Capital collects and analyzes
corporate data to evaluate the 1,000 largest public U.S. companies
across 20 Issues identified through comprehensive, ongoing public
opinion research on Americans’ attitudes toward responsible
corporate behavior. JUST Capital has engaged more than 160,000
participants, on a fully representative basis, since 2015.
Learn more about Merck’s overall commitment to corporate
responsibility, in the latest 2021/2022 ESG Progress Report.
About Merck
At Merck, known as MSD outside of the United States and Canada,
we are unified around our purpose: We use the power of leading-edge
science to save and improve lives around the world. For more than
130 years, we have brought hope to humanity through the development
of important medicines and vaccines. We aspire to be the premier
research-intensive biopharmaceutical company in the world – and
today, we are at the forefront of research to deliver innovative
health solutions that advance the prevention and treatment of
diseases in people and animals. We foster a diverse and inclusive
global workforce and operate responsibly every day to enable a
safe, sustainable and healthy future for all people and
communities. For more information, visit www.merck.com and connect
with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.
About JUST Capital
JUST Capital is an independent nonprofit dedicated to measuring
and improving corporate stakeholder performance – from fair wages
to workforce diversity to climate commitments – at America’s
largest public companies. Our mission is to tackle the most
pressing social challenges of our time by galvanizing the
collective power of corporate America. We believe that business and
markets can and must be a greater force for good, and that by
shifting the resources of the $19 trillion private sector, we can
address systemic issues at scale. Guided by the priorities of the
public, our research, rankings, indexes, and data-driven tools help
deliver on the promise of stakeholder capitalism and an economy
that works for all Americans. JUST Capital publishes the annual
list of America’s Most JUST Companies, the JUST 100, in partnership
with CNBC. To learn more, visit: www.JUSTCapital.com.
Forward-Looking Statement of Merck & Co., Inc., Rahway,
N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA
(the “company”) includes “forward-looking statements” within the
meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of the global outbreak of novel coronavirus disease
(COVID-19); the impact of pharmaceutical industry regulation and
health care legislation in the United States and internationally;
global trends toward health care cost containment; technological
advances, new products and patents attained by competitors;
challenges inherent in new product development, including obtaining
regulatory approval; the company’s ability to accurately predict
future market conditions; manufacturing difficulties or delays;
financial instability of international economies and sovereign
risk; dependence on the effectiveness of the company’s patents and
other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s Annual
Report on Form 10-K for the year ended December 31, 2021 and the
company’s other filings with the Securities and Exchange Commission
(SEC) available at the SEC’s Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230110005333/en/
Media:
Robert Josephson (203) 914-2372
Michael Levey (215) 872-1462
Investor:
Peter Dannenbaum (908) 740-1037
Steven Graziano (908) 740-6582
Merck (NYSE:MRK)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
Von Apr 2023 bis Apr 2024